LCTX

Business Context and Reporting Period

Company: BioTime, Inc. (Note: Input metadata referenced "Lineage Cell Therapeutics," but the filing text identifies the registrant as BioTime, Inc.)
Period: Fiscal year ended December 31, 2009
Business Model: BioTime operates in two segments: (1) Blood plasma volume expanders (primarily Hextend®) for surgery and trauma, and (2) Regenerative medicine focusing on human embryonic stem (hES) and induced pluripotent stem (iPS) cell technology. The company generates revenue primarily through royalties and licensing fees from its plasma products and research grants, while its stem cell therapeutic products remain in preclinical development.

Key Financial Metrics

Note: The company reported a significant increase in cash balances due to equity financing and debt conversion. No profit margins are applicable as the company is pre-profit.

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 28% to $1.93 million, driven largely by the recognition of $552,385 in grant income from the California Institute of Regenerative Medicine (CIRM). Royalty revenues from product sales decreased 10% to $1.08 million, primarily due to reduced sales to the U.S. Armed Forces.
• Expense Increases: R&D expenses rose 72% to $2.97 million, reflecting the company's strategic entry into the stem cell field and increased personnel and laboratory costs. G&A expenses decreased slightly by 5%.
• Debt Elimination: The company retired its entire $3.5 million revolving line of credit during 2009 through an exchange offer converting debt to common shares and warrants. Consequently, interest expense increased significantly due to the accounting treatment of the conversion, but the balance sheet is now debt-free.
• Equity Financing: The company raised $8.0 million in equity capital in 2009 and its subsidiary OncoCyte raised $4.0 million, resulting in a cash position of over $12 million compared to $12,000 at the end of 2008.

Guidance, Outlook, and Risks

• Outlook: Management expects future revenues to depend on royalties from Hextend sales, the CIRM grant (totaling $4.7 million over three years), and potential revenues from new stem cell research products distributed by Millipore Corporation, which began in January 2010.
• Capital Needs: The company states it may need to obtain additional debt or equity capital to finance operations. Future research and clinical study costs are not determinable.
• Risks:
  • Regulatory: Stem cell products require FDA approval for therapeutic use; research products do not. European patent protection for hES cells is uncertain due to regulatory prohibitions.
  • Commercial: Revenue is heavily concentrated; Hospira accounted for 51.9% of 2009 revenues. Sales to the military are intermittent and unpredictable.
  • Development: Therapeutic products (OncoCyte, BioTime Asia) are in early preclinical stages with no assurance of safety, efficacy, or commercialization.

Investor Verification Checklist

• Cash Runway: Verify the burn rate against the $12.2 million cash balance to determine operational runway without further financing.
• Grant Recognition: Confirm the timing of CIRM grant revenue recognition versus cash receipt to understand future revenue visibility.
• Warrant Expiration: Review the terms of the 12.2 million outstanding warrants (mostly expiring Q4 2010) and the proposed discount offer to assess potential dilution.
• Licensee Performance: Monitor Hospira's sales of Hextend, as it remains the primary revenue driver, and assess the impact of military procurement cycles.
• Subsidiary Funding: Verify the funding status of OncoCyte Corporation and BioTime Asia, which rely on parent company capital for clinical trials.